Familiar faces in new leadership roles

Ecorobotix appointed Aurélien G. Demaurex as interim CEO following the unexpected passing of their CEO, Simon Aspinall. Demaurex, the company’s co-founder and CFO, is suited to guide Ecorobotix during this transitional period and will serve as the interim CEO until a new CEO is appointed. With his appointment, Demaurex assures clients, investors, and employees of the company’s continued commitment to further growing the company. Ecorobotix is Certified B Corporation®  which develops and commercializes its agritech product ARA, a revolutionary ultra-high precision sprayer for crop treatment that, combined with theEcorobotix’s plant-by-plant data solution, reduces the use of conventional agricultural inputs by 70-95%, while increasing crop yields by 5% or more and significantly decreasing CO2 emissions. Using AI technology and its unique ultra-high precision spraying system, ARA can recognize individual plants, classify them in real-time, and spray the weeds with an unprecedented precision of 2.4x2.4in (6x6cm) without affecting the surrounding crops or soil.

Antion Biosciences welcomes new CEO
Marco Alessandrini is the new CEO of Antion Biosciences, the startup developing novel gene and gene-modified cell therapies to treat and cure diseases with significant unmet medical needs. The company’s patented proprietary technologies allow for the creation of multimodal treatments that substantially enhance clinical safety and efficacy. Marco is no stranger to Antion; having played a pivotal role as Chief Technical Officer, his dedication and drive for innovation have propelled the company forward and will continue to drive it into the future.

Aison’s funder takes on a new role as Co-CEO
Sophia Borowka, co-founder and CEO of aiSon Technologies, the startup that makes sonography easier by designing tools that accelerate ultrasound procedures and make interventions and diagnostics more accurate, has embarked on a new journey as co-CEO at the 2018 founded company obvioTec AG. This move comes after the company reduced its size due to the challenging economic environment of the past year. Sophia and her team had obtained the CE certification for their medical device, the aiSon FOCUS, the world’s only adaptive ultrasound pad on the market today. During its active operational years, the company continued to grow its customer base, which it will continue to serve on a small scale. Sophia is now taking on a new challenge in deep-tech startup obvioTec AG. “Being both Co-CEOs, my colleague Kaspar Widmer Cantz and I lead a modern company culture by setting a first example. Such a co-leadership is not possible in just any pairing. You have to complement each other, have a similar mindset, values, and, most importantly - the same goals. I look forward to helping both companies grow”, said Sophia in her LinkedIn post. obvioTec AG developed technology to improve pharma quality control and detect fake drugs.

Nanolive appoints new Chief Commercial Officer
Nanolive, a leading provider of phenotypic screening solutions for in vitro live cell imaging and analysis, announced the appointment of Line Stigen Raquet as the new Chief Commercial Officer. With a proven track record as a C-Suite transformational leader and commercial strategist, Line will play a key role in scaling Nanolive’s business performance and driving corporate growth in the competitive life sciences sector. Known for her ability to navigate diverse markets worldwide, Line brings a wealth of experience in global leadership, project management, and enterprise-wide change strategy. Her expertise in establishing and leveraging strong relationships across different cultures has been instrumental in maximizing value creation for industry-leading life sciences organizations. Throughout her career, Line has achieved remarkable success in transforming companies and driving commercial outcomes. She spearheaded the transformation of Creoptix, a startup, into a commercially successful and viable company within 12 months, even amidst the challenges posed by the coronavirus pandemic.

(RAN)